Compare NRIM & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRIM | VNDA |
|---|---|---|
| Founded | 1990 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 602.6M | 301.1M |
| IPO Year | 2002 | 2005 |
| Metric | NRIM | VNDA |
|---|---|---|
| Price | $24.54 | $4.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $30.33 | $11.75 |
| AVG Volume (30 Days) | 117.8K | ★ 598.5K |
| Earning Date | 10-21-2026 | 10-28-2026 |
| Dividend Yield | ★ 2.81% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $255,581,000.00 | $216,105,000.00 |
| Revenue This Year | $1.17 | $15.16 |
| Revenue Next Year | $26.82 | $35.50 |
| P/E Ratio | $18.82 | ★ N/A |
| Revenue Growth | ★ 30.43 | 8.72 |
| 52 Week Low | $19.60 | $4.27 |
| 52 Week High | $30.82 | $9.91 |
| Indicator | NRIM | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 28.92 | 39.46 |
| Support Level | $23.72 | $4.45 |
| Resistance Level | $25.45 | $5.37 |
| Average True Range (ATR) | 0.55 | 0.16 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 7.72 | 8.16 |
Northrim BanCorp Inc is a bank holding company operating through three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. The Community Banking segment, which generates the majority of revenue, provides loan and deposit products to business and consumer customers in its market areas. The Home Mortgage Lending segment focuses on the origination and sale of mortgage loans for one-to-four family residential properties, mortgage loan servicing for certain loans sold, and investment in selected residential mortgage loans. The Specialty Finance segment provides factoring, asset-based lending, and alternative working capital solutions to small and medium-sized enterprises and includes SCF and Northrim Funding Services.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.